Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALP1: Clascoterone for Male Androgenetic Alopecia
NCT05910450Phase 3Completed
- Sponsor
- Cassiopea S.p.A.
- Start
- Jun 2023
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of clascoterone in androgenetic alopecia (AGA), sponsored by Cassiopea S.p.A.. Started Jun 2023; status: completed.
02
Drugs
clascoterone
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05910450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910450.